An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression

An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression

Abstract We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy. We conducted a prospective, interventional, open-label, single-arm, non-randomized study that enrolled 32 patients with IgAN at high risk of progression (BUDIGAN study...

Full description

Bibliographic Details
Main Authors: Bogdan Obrișcă, Alexandra Vornicu, Valentin Mocanu, George Dimofte, Andreea Andronesi, Raluca Bobeică, Roxana Jurubiță, Bogdan Sorohan, Nicu Caceaune, Gener Ismail
Format: Article
Language:English
Published: Nature Portfolio 2023-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-47393-1

Internet

https://doi.org/10.1038/s41598-023-47393-1

Similar Items